Managing Container Closure Related Complexities with Lyophilized Drug Products

To view on-demand, please fill our short form

First Name

Last Name

Company Name

Country

Yes, I would like to receive email updates from West.

By providing your contact information and checking this box, you are consenting to the use of your personal data as described in our Privacy Policy, and assenting to the website Terms and Conditions of Use.

Captcha

Summary
Speakers

The complexities of pharmaceutical drugs begin with development of the molecules and extend through the manufacturing processes and final delivery to patients. Optimal functional performance of these systems relies on predictable and consistent chemical, physical and performance properties. Chemical and physical properties of a container closure system for parenterals may affect the drug manufacturing process, product quality and patient safety.

The potential impact of elastomeric components on product quality and patient safety is well established and addressed by a variety of compendia chapters and regulatory guidance documents. Assessment of Extractables & Leachables, Container Closure Integrity and functional performance are a common part of assessing suitability for intended use of container closure systems.

Design for manufacturability on the other hand, is not as well established and may frequently be an afterthought. In the case of a lyophilized product, significant and additional risks are associated with design for manufacturability and the resulting impact on product quality. Lyophilization stoppers are unique in the fact that they are an integral part of the manufacturing process of a lyophilized drug product. Selection of container closures with optimal design and physical properties can reduce downtime, improve lyophilization performance and overall improve throughput and yields.

Using a comprehensive approach to component selection, ideally early in the drug development process, mitigates risks to fill-finish and lyo processing. The increasing focus on optimal performance of the components and contamination control strategies as part of the manufacturing process does not require compromises to product quality and patient safety. With careful and deliberate selection of container closures, there does not need to be a trade-off between manufacturability, and product quality and patient safety. This free webinar will explore key considerations for selecting lyophilization stoppers suitable for intended use.

Join us to learn more and engage in a conversation with the West Pharmaceutical Services team regarding vial container closure systems for your product development and commercial manufacturing needs.

If you would like to learn more about 4040 LyoTec® stoppers, please visit the product page.

Diego Zurbriggen

Sr. Manager Strategic Studies & Analytical Lifecyle, Scientific Affairs

Mr. Zurbriggen has over 20 years of analytical lab experience, 10 of which focused on inorganic trace level analysis. As Sr. Manager Strategic Studies & Analytical Lifecyle within the Scientific Affairs group of West, the focus of his role is to lead and coordinate scientific content for West products aligned with new pharmaceutical industry expectations and to promote leadership in the pharmaceutical community. Prior to this role, he was Technical Account Manager within the Technical Customer Support group of West, the focus of his role was to provide technical support relating to West’s packaging components and delivery systems for injectable drugs and healthcare products. Mr. Zurbriggen holds a Bachelor of Science/Chemistry degree from the Gewerbliche Berufsschule Visp – Visp, Valais, Switzerland.